Trending
CLM-817766E8
AI-extracted claim
“The drug daraxonrasib, recently approved by the FDA, doubled life expectancy to over 13 months for certain metastatic pancreatic cancer patients in a clinical trial, compared to under 7 months for those on chemotherapy.”
Analyzed on 2026-09-19T07:40:33+00:00 · Last updated 2026-09-19
Unverified
(Unverified)
Plain language: Insufficient evidence was found to render a verdict.
Credibility score
out of 100
Based on 1 source
Low confidence
01
Original context
Show passage from source article
One treatment, daraxonrasib, which just received approval from the Food and Drug Administration, doubled life expectancy in a clinical trial of patients who had previously been treated with chemotherapy for metastatic pancreatic cancer, giving them more than 13 months to live, compared to fewer than seven months for those who received chemotherapy.
Extracted from: I Lost 3 Brothers to Cancer. I’m Determined Not to Be Next. , The New York Times
02
Evidence
1 support
0 contradict
0 context
This analysis is based on a single source. Confidence is low.
Bias distribution of supporting sources
1
← Left
Center
Right →
Mean bias -0.20
05
Community Takes
No Takes have been written on this claim yet. Sign in to write a Take.
06
Metadata
Claim ID
CLM-817766E8
Slug
the-drug-daraxonrasib-recently-approved-by-the-fda-doubled-817766e8
Origin
nytimes.com
Captured
1 d ago
Velocity
0.0/hr
Bias
0.00
Health
Science
Medicine